Literature DB >> 20109055

Liposomal formulations of prilocaine: effect of complexation with hydroxypropyl-ß-cyclodextrin on drug anesthetic efficacy.

Marco Bragagni1, Francesca Maestrelli, Natascia Mennini, Carla Ghelardini, Paola Mura.   

Abstract

A combined strategy, based on cyclodextrin complexation and loading in liposomes, has been investigated to develop a new delivery system with improved therapeutic activity of the local anesthetic, prilocaine (PRL). In order to evaluate the actual effectiveness and advantages of this approach compared to the traditional drug-in-liposome one, four different liposomal formulations were prepared: (1) liposomes loaded with PRL base as complex with hydroxypropyl-β-cyclodextrin (HP CD) in the aqueous phase; (2) liposomes loaded with PRL hydrochloride in the aqueous phase; (3) liposomes loaded with PRL base in the lipophilic phase; and (4) "double-loaded" liposomes, containing free PRL base in the membrane bilayer and its HP CD complex in the aqueous compartment. All batches were characterized for particle size, charge, deformability, and entrapment efficiency from using, respectively, light scattering, extrusion, and dialysis techniques, while the anesthetic effect was evaluated in vivo on Guinea pigs, according to the test of dorsal muscle contraction. All drug liposomal dispersions showed enhanced analgesic duration with respect to the corresponding aqueous solutions, but significant differences were observed between the different formulations. In particular, cyclodextrin complexation not only allowed an efficient encapsulation of PRL base in the aqueous vesicle core, but also increased the anesthetic effect duration and reduced the initial lag time, in comparison with the corresponding formulations containing, respectively, free PRL in the lipophilic phase or PRL hydrochloride in the aqueous vesicle core. The technique of double loading was the most effective, giving rise to the shortest onset time and longest duration of anesthetic effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109055     DOI: 10.3109/08982100903544169

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  7 in total

Review 1.  Safety and efficacy concerns of modern strategies of local anesthetics delivery.

Authors:  Mingxin Ji; Guoliang Liu; Yunfeng Cui; Peng Zhao
Journal:  3 Biotech       Date:  2020-07-06       Impact factor: 2.406

2.  Local toxicity from local anesthetic polymeric microparticles.

Authors:  J Brian McAlvin; Gally Reznor; Sahadev A Shankarappa; Cristina F Stefanescu; Daniel S Kohane
Journal:  Anesth Analg       Date:  2013-03-04       Impact factor: 5.108

3.  New formulations of local anaesthetics-part I.

Authors:  Edward A Shipton
Journal:  Anesthesiol Res Pract       Date:  2011-12-05

4.  Injectable liposomal formulations of opiorphin as a new therapeutic strategy in pain management.

Authors:  Natascia Mennini; Paola Mura; Cristina Nativi; Barbara Richichi; Lorenzo Di Cesare Mannelli; Carla Ghelardini
Journal:  Future Sci OA       Date:  2015-11-01

5.  Novel Findings about Double-Loaded Curcumin-in-HPβcyclodextrin-in Liposomes: Effects on the Lipid Bilayer and Drug Release.

Authors:  Ana-María Fernández-Romero; Francesca Maestrelli; Paola Angela Mura; Antonio María Rabasco; María Luisa González-Rodríguez
Journal:  Pharmaceutics       Date:  2018-12-03       Impact factor: 6.321

6.  Encapsulation of α-Pinene in Delivery Systems Based on Liposomes and Cyclodextrins.

Authors:  Zahraa Hammoud; Maya Kayouka; Adriana Trifan; Elwira Sieniawska; Jouda Mediouni Ben Jemâa; Abdelhamid Elaissari; Hélène Greige-Gerges
Journal:  Molecules       Date:  2021-11-12       Impact factor: 4.411

7.  Improvement of Butamben Anesthetic Efficacy by the Development of Deformable Liposomes Bearing the Drug as Cyclodextrin Complex.

Authors:  Paola Mura; Francesca Maestrelli; Marzia Cirri; Giulia Nerli; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Natascia Mennini
Journal:  Pharmaceutics       Date:  2021-06-12       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.